Race Oncology

Update in progress

RAC.AX (ASX)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Racura Oncology Ltd is a Phase 3 cancer biopharma focused on advancing its lead asset, RCDS1 (E,E-bisantrene), a small-molecule that binds G4-DNA and RNA to inhibit the cancer growth regulator MYC. Its proprietary RC220 formulation is in Phase 3 for acute myeloid leukemia, with Phase 1/1b programs in EGFRm NSCLC and in combination with doxorubicin. It collaborates with Astex, MD Anderson, Sheba, UNC, and universities in Australia. Formerly Race Oncology Ltd, renamed in Dec 2025. Founded 2011, based in Sydney.

Company score

Sentiment: 0.42; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.28; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive